<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03880487</url>
  </required_header>
  <id_info>
    <org_study_id>KP-1199-CP-001</org_study_id>
    <secondary_id>CDMRP-OR 160158</secondary_id>
    <nct_id>NCT03880487</nct_id>
  </id_info>
  <brief_title>A Single and Multiple Ascending Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of KP-1199</brief_title>
  <official_title>A Randomized, Placebo- and Active-Controlled, Double-Blind, Single and Multiple Ascending Dose Study in Healthy Adults to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KP-1199</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kalyra Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>PRA Health Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kalyra Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, randomized, placebo and active-controlled, double blind, single and
      multiple ascending dose study in healthy adults to evaluate the safety, tolerability,
      pharmacokinetics and preliminary efficacy of KP-1199
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Treatment Emergent Adverse Events</measure>
    <time_frame>Part 1: From Day 1 through Day 6, Part 2: From Day 1 through Day 11, Part 3: From Day 1 through Day 12</time_frame>
    <description>Number of treatment related adverse events as determined by abnormal clinical laboratory tests, vitals signs, physical exam, ECG parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of KP-1199 to measure plasma concentration of KP-1199</measure>
    <time_frame>Part 1: Day 1 (pre-dose through 4 hours after dose administration), Part 2: (pre-dose through Day 8), Part 3: (pre-dose through Day 7)</time_frame>
    <description>Maximum Observed Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of KP-1199 to measure Time to Maximum plasma concentration of KP-1199</measure>
    <time_frame>Part 1: Day 1 (pre-dose through 4 hours after dose administration), Part 2: (pre-dose through Day 8), Part 3: (pre-dose through Day 7)</time_frame>
    <description>Time to Maximum Plasma Concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of KP-1199 to measure area under curve plasma concentration of KP-1199</measure>
    <time_frame>Part 1: Day 1 (pre-dose through 4 hours after dose administration), Part 2: (pre-dose through Day 8), Part 3: (pre-dose through Day 7)</time_frame>
    <description>Area Under the Concentration-time Curve Up to Time (t), where t is the last point with concentrations above the lower limit of quantitation (AUC0-t) Area Under the Concentration-time Curve for 1 dosing interval of a multiple dose regimen (AUCtau)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of KP-1199 to measure plasma terminal half-life concentration of KP-1199</measure>
    <time_frame>Part 1: Day 1 (pre-dose through 4 hours after dose administration), Part 2: (pre-dose through Day 8), Part 3: (pre-dose through Day 7)</time_frame>
    <description>The Apparent Terminal Elimination Half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile of KP-1199 to measure the trough plasma concentration of KP-1199</measure>
    <time_frame>Part 1: Day 1 (pre-dose through 4 hours after dose administration), Part 2: (pre-dose through Day 8), Part 3: (pre-dose through Day 7)</time_frame>
    <description>Trough Plasma Concentration (Ctrough)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Effects of KP-1199 using Cold Pressor Test to measure pain threshold</measure>
    <time_frame>Part 3: Day 1, Day 3, Day 5 and Day 7 (pre-dose through 6 hours after dose administration)</time_frame>
    <description>Time to feel first pain (&quot;pain threshold&quot; measured in seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Effects of KP-1199 using Cold Pressor Test to measure pain tolerance</measure>
    <time_frame>Part 3: Day 1, Day 3, Day 5 and Day 7 (pre-dose through 6 hours after dose administration)</time_frame>
    <description>Time to withdrawal of hand from cold water (&quot;Pain tolerance&quot; in seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Effects of KP-1199 using Cold Pressor Test</measure>
    <time_frame>Part 3: Day 1, Day 3, Day 5 and Day 7 (pre-dose through 6 hours after dose administration)</time_frame>
    <description>Pain tolerance will be measured at time of hand withdrawal using a 11-point (0-10) Numeric Pain Rating Scale (NPRS) where &quot;0 (no pain) to 10 (worst pain)&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Effects of KP-1199 using Ultraviolet Burn Model (UVB)</measure>
    <time_frame>Part 3: Day 1, Day 3, Day 5 and Day 7 (pre-dose through 6 hours after dose administration)</time_frame>
    <description>Neurosensory Testing (change in neurosensory assessments of the skin at site of ultraviolet burn)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">97</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>KP-1199</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxycodone oral capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KP-1199</intervention_name>
    <description>Single dose and Multiple ascending doses of KP-1199 oral capsules</description>
    <arm_group_label>KP-1199</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Single dose and Multiple dose identical to active treatment but without KP-1199.</description>
    <arm_group_label>Placebo oral capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone oral capsule</intervention_name>
    <description>10 mg Oxycodone Capsules</description>
    <arm_group_label>Oxycodone oral capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Adult 18-45 years of age at time of screening, inclusive.

          -  Have a body mass index (BMI) between 18.0 and ≤32 kg/m2, inclusive, and a weight of
             ≥50 kg at screening.

          -  Be determined to be healthy on the basis of a pre-study physical examination, medical
             history review, vital sign measurements, and the results of laboratory tests.

          -  For both male and females: using acceptable method of birth control

          -  If Female: not-pregnant or not breast feeding and not planning on becoming pregnant

          -  All prescribed medication must have been stopped at least 14 days prior to admission
             to the clinical research site. An exception is made for hormonal contraceptives, which
             may be used throughout the study.

          -  All over-the-counter medication, vitamin preparations and other food supplements, or
             herbal medications (eg, St. John's Wort) must have been stopped at least 14 days prior
             to admission to the clinical research site.

          -  Must be adequately informed and understand the nature and risks of the study and must
             provide written informed consent prior to enrollment at screening.

        Exclusion Criteria:

          -  Subjects who participate in one part of the study are not eligible to participate in
             subsequent parts of the study.

          -  Women who are pregnant, lactating, or planning to attempt to become pregnant during
             this study or within 90 days after the follow-up visit.

          -  Males with female partners who are planning to attempt to become pregnant during this
             study or within 90 days after the follow-up visit.

          -  History or evidence of significant clinical or psychiatric disorder, condition, or
             disease that, in the opinion of the Investigator would pose an unacceptable risk to
             the subject safety or interfere with the study evaluations, procedures, or completion
             of the study.

          -  Documented congenital QT syndrome, and/or corrected QT interval (Fridericia
             correction; QTcF) at screening or first admission &gt; 450 ms.

          -  Positive screening test for hepatitis B surface antigen, anti-hepatitis C virus
             antibodies or anti-human immunodeficiency virus 1 and 2 antibodies.

          -  History of drug allergy diagnosed by a physician.

          -  Use of tobacco within 30 days prior to the first study drug administration.

          -  History of alcohol consumption exceeding 2 standard drinks per day on average.

          -  Routine or chronic use of more than 0.5 grams of acetaminophen daily.

          -  History of donation of more than 450 mL of blood within 60 days prior to dosing in the
             clinical research site or planned donation before 30 days has elapsed since intake of
             study drug.

          -  Plasma or platelet donation within 7 days of dosing

          -  Use of any investigational drug or device within 30 days of the first dose of study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Bunker, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kalyra Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian F Kenney</last_name>
    <phone>8582634333</phone>
    <email>info@kalyrapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam Mackin</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I, Healthy Adult Participants</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

